Ann Dermatol.  2012 Aug;24(3):380-382. 10.5021/ad.2012.24.3.380.

Successful Treatment of Xanthoma Disseminatum with Combined Lipid Lowering Agents

• Kim WJ
• Ko HC
• Kim BS
• Kim MB

• KMID: 2265321
• DOI: http://doi.org/10.5021/ad.2012.24.3.380

Abstract

No abstract available.

MeSH Terms

Histiocytosis, Non-Langerhans-Cell
Xanthomatosis

Figure

• 

  Fig. 1 Multiple well-defined yellow-brownish various sized papulonodular skin lesions on right axilla (A), eyelids (B), and buttock (C).

• 

  Fig. 2 Markedly flattened yellow-brownish papulonodules on both axillae (A: right, B: left) after 1 year of lipid-lowering agents in combination.

Reference

1. Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol. 1985. 13:1–30.

2. Kim JY, Jung HD, Choe YS, Lee WJ, Lee SJ, Kim do W, et al. A case of xanthoma disseminatum accentuating over the eyelids. Ann Dermatol. 2010. 22:353–357.

3. Burgdorf WH, Zelger B. Elder DE, Elenitsas R, Johnson BL, editors. The histiocytosis. Lever's histopathology of the skin. 2009. 10th ed. Philadelphia: Lippincott Williams & Wilkins;667–688.

4. Joshi PH, Jacobson TA. Therapeutic options to further lower C-reactive protein for patients on statin treatment. Curr Atheroscler Rep. 2010. 12:34–42.

5. Eisendle K, Linder D, Ratzinger G, Zelger B, Philipp W, Piza H, et al. Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations. J Am Acad Dermatol. 2008. 58:2 Suppl. S47–S49.

6. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998. 391:82–86.

7. Alagona P Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag. 2010. 6:351–362.

8. Yiu KH, Cheung BM, Tse HF. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. Expert Opin Investig Drugs. 2010. 19:437–449.